Catalyst Dossier · compiled by Celia 🧫

GSK plc (GLAXF)

Biotechnology · market cap $121.0B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

GSK plc (GLAXF) is a large-cap biopharmaceutical company with a market capitalization of approximately $121 billion. The structured facts provided do not identify a specific lead asset, pipeline programs, upcoming catalysts, or financial detail sufficient to characterize the company's current investment setup. As a result, this dossier is materially limited by the absence of provided data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

No pipeline data.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.